Skip to main content

Combined Multi-marker Screening and Randomised Patient Treatment with Aspirin for Evidence-based Pre-eclampsia Prevention

Objective

"Project ASPRE is a commercially led development project that aims to boost translation of the results of PREGENESYS (FP6 EU #37244) into effective applications for prenatal care. PREGENESYS has identified several biomarkers for early (11-13 weeks’ gestation) and effective identification of pregnancies at high risk of developing pre-eclampsia (PE). This disorder affects 2-8% of pregnant women and is a major cause of short- and long-term maternal and perinatal morbidity and mortality. Studies under PREGENESYS using in-vitro research methods suggested that aspirin is the most promising agent for preventing PE. Evidence from small clinical studies has indicated that prophylactic use of low-dose aspirin starting before 16 weeks’ gestation can potentially halve the PE prevalence and its associated complications. Objectives: Widespread clinical implementation of a strategy of screening and prevention of PE: (1) Reduce the prevalence of PE requiring delivery before 37 weeks (preterm PE) by at least 50%, (2) Demonstrate through a large multicentre screening and prevention study the acceptability, uptake and efficacy of first trimester multi-parameter screening of preterm PE and its preventative treatment with aspirin, (3) Develop affordable, automated and reliable methods for high throughput measurement of biomarkers and commercial platforms for PE risk assessment software, (4) Develop management protocols for high risk and low risk pregnancies for PE, (5) Improve education and training of healthcare professionals involved in pregnancy care, (6) Conduct the dissemination and training required to drive clinical acceptance and adoption of multi-parameter PE screening and aspirin treatment. Expected results and impact: Generating a market demand for SME-based newly developed products for PE screening and prevention, including machines, kits and software, thereby transforming research success into economic growth for SMEs and upholding European leadership in perinatal care."

Field of science

  • /social sciences/economics and business/business and management/commerce
  • /natural sciences/computer and information sciences/software
  • /social sciences/sociology/demography/mortality

Call for proposal

FP7-HEALTH-2013-INNOVATION-2
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

FETAL MEDICINE FOUNDATION
Address
Harley Street 137
W1G 6BG London
United Kingdom
Activity type
Research Organisations
EU contribution
€ 2 275 156,60
Administrative Contact
Thanos Kotsis (Mr.)

Participants (4)

HY LABORATORIES LTD
Israel
EU contribution
€ 2 013 546,90
Address
Menachem Plaut Str Park Tamar 6
76326 Rehovot
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Winkler Or (Mr.)
HANANJA EHF
Iceland
EU contribution
€ 473 693,20
Address
Aflagranda 7
107 Reykjavik
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Kristin Linda Ragnarsdottir (Ms.)
ASTRAIA SOFTWARE GMBH
Germany
EU contribution
€ 567 799,60
Address
Occam Strasse 20
80802 Munchen
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Angela Döring (Ms.)
WALLAC OY
Finland
EU contribution
€ 509 603,70
Address
Mustionkatu 6
20750 Turku
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Tarja Ahola (Ms.)